Status:
COMPLETED
Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
Lead Sponsor:
Revotar Biopharmaceuticals AG
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.
Eligibility Criteria
Inclusion
- Clinical diagnosis of plaque type psoriasis PASI score of 5-15
- At least 18 years of age
- Written informed consent
Exclusion
- Active skin infection
- More than 20% Body Surface Area (BSA) affected by psoriasis
- Use of certain anti-psoriasis medication or treatments
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT00823693
Last Update
August 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie
Berlin, Germany